

Why is the T-cell Immunoreceptor with Ig and ITIM Domains (TIGIT) Pathway a Promising Cancer Treatment Target?

TOOLKIT

Resources	Address
Banta KL, Xu X, Chitre AS, et al. Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8 ⁺ T cell responses. <i>Immunity</i> . 2022;55(3):512-526.e9.	https://pubmed.ncbi.nlm.nih.gov/35263569/
Bendell JC, Bedard P, Bang YJ, et al: Phase Ia/Ib dose-escalation study of the anti-TIGIT antibody tiragolumab as a single agent and in combination with atezolizumab in patients with advanced solid tumors. 2020 AACR Virtual Annual Meeting II. Abstract CT302.	https://www.abstractsonline.com/pp8/#!/9045/presentation/11341
Cancer Research Institute. PD-1/PD-L1 Landscape.	www.cancerresearch.org/en-us/scientists/immuno-oncology-landscape/pd-1-pd-l1-landscape#landscape
Chauvin JM, Ka M, Pagliano O, et al. IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma. <i>Clin Cancer Res</i> . 2020;26(20):5520-5533.	https://pubmed.ncbi.nlm.nih.gov/32591463/
Chauvin JM, Pagliano O, Fourcade J, et al. TIGIT and PD-1 impair tumor antigen-specific CD8 ⁺ T cells in melanoma patients. <i>J Clin Invest</i> . 2015;125(5):2046-2058	https://pubmed.ncbi.nlm.nih.gov/25866972/
Chauvin JM, Zarour HM. TIGIT in cancer immunotherapy. <i>J Immunother Cancer</i> . 2020;8(2):e000957.	https://pubmed.ncbi.nlm.nih.gov/32900861/
Du X, de Almeida P, Manieri N, et al. CD226 regulates natural killer cell antitumor responses via phosphorylation-mediated inactivation of transcription factor FOXO1. <i>Proc Natl Acad Sci U S A</i> . 2018;115(50):E11731-E11740.	https://pubmed.ncbi.nlm.nih.gov/30504141/
Fourcade J, Sun Z, Chauvin JM, et al. CD226 opposes TIGIT to disrupt Tregs in melanoma. <i>JCI Insight</i> . 2018;3(14):e121157.	https://pubmed.ncbi.nlm.nih.gov/30046006/
Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. <i>N Engl J Med</i> . 2018;378(22):2078-2092.	https://pubmed.ncbi.nlm.nih.gov/29658856/

Garon EB, Hellmann MD, Rizvi NA, et al. Five-Year Overall Survival for Patients With Advanced Non–Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. <i>J Clin Oncol</i> . 2019;37(28):2518-2527.	https://pubmed.ncbi.nlm.nih.gov/31154919/
Han JH, Cai M, Grein J, et al. Corrigendum: Effective Anti-tumor Response by TIGIT Blockade Associated With FcγR Engagement and Myeloid Cell Activation. <i>Front Immunol</i> . 2020;11:615755.	https://pubmed.ncbi.nlm.nih.gov/33329611/
Johnston RJ, Comps-Agrar L, Hackney J, et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. <i>Cancer Cell</i> . 2014;26(6):923-937.	https://pubmed.ncbi.nlm.nih.gov/25465800/
Kurtulus S, Sakuishi K, Ngiow SF, et al. TIGIT predominantly regulates the immune response via regulatory T cells. <i>J Clin Invest</i> . 2015;125(11):4053-4062	https://pubmed.ncbi.nlm.nih.gov/26413872/
Manieri NA, Chiang EY, Grogan JL. TIGIT: A Key Inhibitor of the Cancer Immunity Cycle. <i>Trends Immunol</i> . 2017;38(1):20-28.	https://pubmed.ncbi.nlm.nih.gov/27793572/
Mittal D, Lepletier A, Madore J, et al. CD96 Is an Immune Checkpoint That Regulates CD8 ⁺ T-cell Antitumor Function. <i>Cancer Immunol Res</i> . 2019;7(4):559-571.	https://pubmed.ncbi.nlm.nih.gov/30894377/
Niu J, et al. Safety and efficacy of vibostolimab, an anti-TIGIT antibody, plus pembrolizumab in patients with anti-PD-1/PD-L1-naïve NSCLC. <i>Ann Oncology</i> . 2020;31(suppl 4):S891-S892.	https://www.annalsofoncology.org/article/S0923-7534(20)41720-X/fulltext#relatedArticles
Niu J, Maurice-Dror C, Lee DH, et al. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer.. <i>Ann Oncol</i> . 2022;33(2):169-180.	https://pubmed.ncbi.nlm.nih.gov/34800678/
Paz-Ares L, Ciuleanu TE, Cobo M, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial [published correction appears in Lancet Oncol. 2021 Mar;22(3):e92]. <i>Lancet Oncol</i> . 2021;22(2):198-211	https://pubmed.ncbi.nlm.nih.gov/33476593/
Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus Chemotherapy for	https://pubmed.ncbi.nlm.nih.gov/30280635/

Squamous Non-Small-Cell Lung Cancer. <i>N Engl J Med</i> . 2018;379(21):2040-2051.	
Paz-Ares LG, Ramalingam SS, Ciuleanu TE, et al. First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. <i>J Thorac Oncol</i> . 2022;17(2):289-308.	https://pubmed.ncbi.nlm.nih.gov/34648948/
Reck M, Ciuleanu TE, Cobo M, et al. First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update. <i>ESMO Open</i> . 2021;6(5):100273.	https://pubmed.ncbi.nlm.nih.gov/34607285/
Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. <i>Science</i> . 2018;359(6382):1350-1355.	https://pubmed.ncbi.nlm.nih.gov/29567705/
Roche [press release]. Roche provides update on phase 3 SKYSCRAPER-02 study in extensive-stage small cell lung cancer	www.roche.com/media/releases/med-cor-2022-03-30
Rodriguez-Abreu D, Johnson ML, Hussein MA, et al. Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE). <i>J Clin Oncol</i> . 2020;38(15_suppl):9503-9503.	https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.9503
Rotte A, Sahasranaman S, Budha N. Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical Development. <i>Biomedicines</i> . 2021;9(9):1277.	https://pubmed.ncbi.nlm.nih.gov/34572463/
Waight JD, Chand D, Dietrich S, et al. Selective FcγR Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens. <i>Cancer Cell</i> . 2018;33(6):1033-1047.e5	https://pubmed.ncbi.nlm.nih.gov/29894690/